


### ■ RSA;11 cells

Human RS4;11 cells were isolated from the bone marrow a patient with Acute Lymphoblastic Leukemia.

### ■ Tumour growth *in vivo*

The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers, and extrapolating the volume to a sphere.

The mice bearing RS4;11 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or subcutaneous injection of the compounds. *Per os* administration is also possible.




**Figure 1:** Tumour growth curve of the RS4;11 cells as xenograft  
Mean  $\pm$  SEM (n=7; take rate 100%)

Antineo can also perform an IV implantation, using hCD45 Flow Cytometry as follow-up of tumour progression.

### ■ Standard-Of-Care Drug Responses

Rituximab, 30 mg/kg, bi-weekly  $\rightarrow$  No Response



**Figure 2:** Effect of rituximab or dexamethasone on RS4;11 tumour growth  
Mean  $\pm$  SEM (n=6 per group; take rate 100%)